The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Open accessAbstract
CRISPR RNA-guided nucleases (RGNs) are widely used genome-editing reagents, but methods to delineate their genome-wide, off-target cleavage activities have been lacking. Here we describe an approach for global detection of DNA double-stranded breaks (DSBs) introduced by RGNs and potentially other nucleases. This method, called genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq), relies on capture of double-stranded oligodeoxynucleotides into DSBs. Application of GUIDE-seq to 13 RGNs in two human cell lines revealed wide variability in RGN off-target activities and unappreciated characteristics of off-target sequences. The majority of identified sites were not detected by existing computational methods or chromatin immunoprecipitation sequencing (ChIP-seq). GUIDE-seq also identified RGN-independent genomic breakpoint 'hotspots'. Finally, GUIDE-seq revealed that truncated guide RNAs exhibit substantially reduced RGN-induced, off-target DSBs. Our experiments define the most rigorous framework for genome-wide identification of RGN off-target effects to date and provide a method for evaluating the safety of these nucleases before clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A primary limitation of GUIDE-seq is relevant to the low delivery efficiency of dsODNs into cells, which results in detection of only 30%–50% of all the DSBs (Tsai et al., 2015; Pan et al., 2022).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Off-target profiling of AsCas12a-crRNA+11 genome editing in HEK293/3272-26A>G cells18,42 showed very high specificity, as demonstrated by exclusive editing of the 3272-26A>G CFTR locus, while non-specific cleavages in the second allele, or any other genomic loci, could not be detected (Fig. 2c and Supplementary Fig. 4c).”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The major barrier of clinical use of CRISPR/Cas9 is its off-target effects [81,82,83].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While cleavage at sites with perfect complementarity to the protospacer domain of the gRNA typically occurs with highest efficiency, cleavage at sites having one to several bases of mismatch with the gRNA can occur. These undesired cleavage events are called “off-target effects” (OTEs)10, and their existence should be minimized for therapeutic applications of genome editing technologies.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The GUIDE-seq procedure10 can be used to empirically identify real off-target sites in cells.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq can detect off-target sites with indel frequencies as low as 0.03% (Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq is more sensitive than the IDLV method because dsODNs integrate more efficiently and precisely into DSBs, while the integration events of IDLV is low in number and can distribute as far as 500bp away from the actual DSB sites (Tsai et al., 2015; Cromer et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“However, other publications observed a much lower validation rate (Cencic et al., 2014; Duan et al., 2014; Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“These studies indicated that Cas9 could associate with genomic loci without exerting its nuclease function, deposing a major caveat in Cas9 ChIP-Seq-based off-target detection assay.”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, compared to cell-based methods such as GUIDE-seq (see next section) (Tsai et al., 2015), Extru-seq exhibited much lower false negative rate (2.3% versus 29%) (Kwon et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
In the citing paper
“Using the standard Guide-seq protocol, we detected only the Fah target site and one off-target site (defined as Guide-seq off-target site 1, or GOT1) (Supplementary Data Set 1).”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [23]
In the citing paper
“However, silicon methods can only identify part of the off-target cleavage.48”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citationCRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Self-citationRNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
Cited by
Sorted by citations
Items 101–200 of 1,009
Increasing the specificity of CRISPR systems with engineered RNA secondary structures
Kocak, D. D., Josephs, E. A., Bhandarkar, V., Adkar, S. S., Kwon, J. B., & Gersbach, C. A. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0095-1 · Cited by 351
Disabling Cas9 by an anti-CRISPR DNA mimic
Shin, J. J., Jiang, F., Liu, J., Bray, N., Rauch, B. J., Baik, R., Nogales, E., Bondy‐Denomy, J., Corn, J. E., & Doudna, J. A. (2017) · Science Advances · doi:10.1126/sciadv.1701620 · Cited by 358
Continuous evolution of base editors with expanded target compatibility and improved activity
Thuronyi, B. W., Koblan, L. W., Levy, J. M., Yeh, W.-H., Zheng, C., Newby, G. A., Wilson, C., Bhaumik, M., Shubina-Oleinik, O., Holt, J. R., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0193-0 · Cited by 347
Continuous evolution of SpCas9 variants compatible with non-G PAMs
Miller, S. M., Wang, T., Randolph, P. B., Arbab, M., Shen, M. W., Huang, T. P., Matuszek, Ż., Newby, G. A., Rees, H. A., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0412-8 · Cited by 359
Optimized base editors enable efficient editing in cells, organoids and mice
Zafra, M. P., Schatoff, E. M., Katti, A., Foronda, M., Breinig, M., Schweitzer, A. Y., Simon, A., Han, T., Goswami, S., Montgomery, E., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4194 · Cited by 347
Mangeot, P. E., Risson, V., Fusil, F., Marnef, A., Laurent, E., Blin, J., Mournetas, V., Massouridès, E., Sohier, T. J. M., Corbin, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07845-z · Cited by 346
Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens
Morgens, D. W., Wainberg, M., Boyle, E. A., Ursu, O., Araya, C. L., Tsui, C. K., Haney, M. S., Hess, G. T., Han, K., Jeng, E. E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15178 · Cited by 362
Gene editing in plants: progress and challenges
Mao, Y., Botella, J. R., Liu, Y., & Zhu, J. (2019) · National Science Review · doi:10.1093/nsr/nwz005 · Cited by 353
Schiroli, G., Conti, A., Ferrari, S., della Volpe, L., Jacob, A., Albano, L., Beretta, S., Calabria, A., Vavassori, V., Gasparini, P., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.02.019 · Cited by 342
Yan, S., Tu, Z., Liu, Z., Fan, N., Yang, H., Yang, S., Yang, W., Zhao, Y., Ouyang, Z., Lai, C., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.005 · Cited by 349
Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs
Listgarten, J., Weinstein, M., Kleinstiver, B. P., Sousa, A. A., Joung, J. K., Crawford, J., Gao, K., Hoang, L., Elibol, M., Doench, J. G., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0178-6 · Cited by 336
Self-citationCRISPR/Cas9 for cancer research and therapy
Zhan, T., Rindtorff, N., Betge, J., Ebert, M., & Boutros, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 338
CRISPR DNA base editors with reduced RNA off-target and self-editing activities
Grünewald, J., Zhou, R., Iyer, S., Lareau, C. A., Garcia, S. P., Aryee, M. J., & Joung, J. K. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0236-6 · Cited by 332
Self-citationOrigins of Programmable Nucleases for Genome Engineering
Chandrasegaran, S., & Carroll, D. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.10.014 · Cited by 344
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
Wang, X., Wu, X., Tan, B., Zhu, L., Zhang, Y., Li, L., Xiao, Y., Sun, A., Wan, X., Liu, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.027 · Cited by 334
Zischewski, J., Fischer, R., & Bortesi, L. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.12.003 · Cited by 323
In vivo CRISPR editing with no detectable genome-wide off-target mutations
Akçakaya, P., Bobbin, M. L., Guo, J. A., Malagon-Lopez, J., Clement, K., Garcia, S. P., Fellows, M. D., Porritt, M. J., Firth, M. A., Carreras, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0500-9 · Cited by 324
Self-citationCRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo
Mas, A., Ebanks, S., Keiser, M. S., & Davidson, B. L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.010 · Cited by 326
Tang, X. D., Liu, G., Zhou, J., Ren, Q., You, Q., Tian, L., Xin, X., Zhong, Z., Liu, B., Zheng, X., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1458-5 · Cited by 313
Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity
Tycko, J., Myer, V. E., & Hsu, P. D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.07.004 · Cited by 315
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
Daher, M., Başar, R., Gokdemir, E., Baran, N., Uprety, N., Cortes, A. K. N., Mendt, M. C., Kerbauy, L. N., Banerjee, P. P., Shanley, M., et al. (2020) · Blood · doi:10.1182/blood.2020007748 · Cited by 314
CRISPR/Cas9-mediated efficient targeted mutagenesis in Chardonnay (Vitis vinifera L.)
Ren, C., Liu, X., Zhang, Z., Wang, Y., Duan, W., Li, S., & Liang, Z. (2016) · Scientific Reports · doi:10.1038/srep32289 · Cited by 310
Park, C., Kim, D. H., Sung, J. J., Sung, J. J., Lee, J., Bae, S., Kim, D., Kim, D., & Kim, J. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.07.001 · Cited by 305
Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice
Aida, T., Chiyo, K., Usami, T., Ishikubo, H., Imahashi, R., Wada, Y., Tanaka, K. F., Sakuma, T., Yamamoto, T., & Tanaka, K. (2015) · Genome biology · doi:10.1186/s13059-015-0653-x · Cited by 298
In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models
Yin, C., Zhang, T., Qu, X., Zhang, Y., Putatunda, R., Xiao, X., Li, F., Xiao, W., Zhao, H., Dai, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.012 · Cited by 273
Renaud, J.-B., Boix, C., Charpentier, M., Cian, A. D., Cochennec, J., Duvernois‐Berthet, E., Perrouault, L., Tesson, L., Edouard, J., Thinard, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.018 · Cited by 295
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S., & Chakraborty, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 310
A conformational checkpoint between DNA binding and cleavage by CRISPR-Cas9
Dagdas, Y. S., Chen, J. S., Sternberg, S. H., Doudna, J. A., & Yildiz, A. (2017) · Science Advances · doi:10.1126/sciadv.aao0027 · Cited by 293
CRISPR Crops: Plant Genome Editing Toward Disease Resistance
Langner, T., Kamoun, S., & Belhaj, K. (2018) · Annual Review of Phytopathology · doi:10.1146/annurev-phyto-080417-050158 · Cited by 301
DNA Breaks and End Resection Measured Genome-wide by End Sequencing
Canela, A., Sridharan, S., Sciascia, N., Tubbs, A., Meltzer, P., Sleckman, B. P., & Nussenzweig, A. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.034 · Cited by 284
Applications of CRISPR–Cas systems in neuroscience
Heidenreich, M., & Zhang, F. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn.2015.2 · Cited by 290
CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity
Lazzarotto, C. R., Malinin, N. L., Li, Y., Zhang, R., Yang, Y., Lee, G., Cowley, E., He, Y., Lan, X., Jividen, K., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0555-7 · Cited by 294
Self-citationFriedland, A. E., Baral, R., Singhal, P., Loveluck, K., Shen, S., Sanchez, M. E., Marco, E., Gotta, G. M., Maeder, M. L., Kennedy, E. M., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0817-8 · Cited by 285
Efficient CRISPR/Cas9-based gene knockout in watermelon
Tian, S., Jiang, L., Gao, Q., Zhang, J., Zong, M., Zhang, H., Ren, Y., Guo, S., Gong, G., Liu, F., et al. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-2089-5 · Cited by 278
Analysis and minimization of cellular RNA editing by DNA adenine base editors
Rees, H. A., Wilson, C., Doman, J. L., & Liu, D. R. (2019) · Science Advances · doi:10.1126/sciadv.aax5717 · Cited by 282
Viral Delivery Systems for CRISPR
Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (2019) · Viruses · doi:10.3390/v11010028 · Cited by 277
Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors
Huang, T. P., Zhao, K. T., Miller, S. M., Gaudelli, N. M., Oakes, B. L., Fellmann, C., Savage, D. F., & Liu, D. R. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0134-y · Cited by 282
Genome-wide target specificities of CRISPR RNA-guided programmable deaminases
Kim, D., Lim, K., Kim, S., Yoon, S.-H., Kim, K., Ryu, S.-M., & Kim, J. (2017) · Nature Biotechnology · doi:10.1038/nbt.3852 · Cited by 281
Precision genome editing in plants: state-of-the-art in CRISPR/Cas9-based genome engineering
Wada, N., Ueta, R., Osakabe, Y., & Osakabe, K. (2020) · BMC Plant Biology · doi:10.1186/s12870-020-02385-5 · Cited by 279
Structural basis for mismatch surveillance by CRISPR–Cas9
Bravo, J. P. K., Liu, M., Hibshman, G. N., Dangerfield, T. L., Jung, K., McCool, R. S., Johnson, K. A., & Taylor, D. W. (2022) · Nature · doi:10.1038/s41586-022-04470-1 · Cited by 282
A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing
Edraki, A., Mir, A., Ibraheim, R., Gainetdinov, I., Yoon, Y., Song, C.-Q., Cao, Y., Gallant, J., Xue, W., Rivera-Pérez, J. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.003 · Cited by 265
Hoshijima, K., Jurynec, M. J., Shaw, D. K., Jacobi, A. M., Behlke, M. A., & Grunwald, D. J. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.10.004 · Cited by 274
CRISPR technologies for genome, epigenome and transcriptome editing
Villiger, L., Joung, J., Koblan, L. W., Weissman, J. S., Abudayyeh, O. O., & Gootenberg, J. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00697-6 · Cited by 280
Self-citationKang, X., He, W., Huang, Y., Qian, Y., Chen, Y., Gao, X., Sun, X., & Fan, Y. (2016) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-016-0710-8 · Cited by 271
Improving prime editing with an endogenous small RNA-binding protein
Yan, J., Oyler-Castrillo, P., Ravisankar, P., Ward, C. C., Levesque, S., Jing, Y., Simpson, D., Zhao, A., Li, H. Z., Yan, W., et al. (2024) · Nature · doi:10.1038/s41586-024-07259-6 · Cited by 274
Systematic gene tagging using CRISPR/Cas9 in human stem cells to illuminate cell organization
Roberts, B., Haupt, A., Tucker, A., Grancharova, T., Arakaki, J., Fuqua, M. A., Nelson, A., Hookway, C., Ludmann, S. A., Mueller, I. A., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-03-0209 · Cited by 262
Hu, J., Meyers, R. M., Dong, J., Panchakshari, R. A., Alt, F. W., & Frock, R. L. (2016) · Nature Protocols · doi:10.1038/nprot.2016.043 · Cited by 274
Miyaoka, Y., Berman, J. R., Cooper, S., Mayerl, S. J., Chan, A. H., Zhang, B., Karlin-Neumann, G. A., & Conklin, B. R. (2016) · Scientific Reports · doi:10.1038/srep23549 · Cited by 277
Advances in therapeutic CRISPR/Cas9 genome editing
Savić, N., & Schwank, G. (2016) · Translational Research · doi:10.1016/j.trsl.2015.09.008 · Cited by 257
Real-time observation of DNA recognition and rejection by the RNA-guided endonuclease Cas9
Singh, D., Sternberg, S. H., Fei, J., Doudna, J. A., & Ha, T. (2016) · Nature Communications · doi:10.1038/ncomms12778 · Cited by 269
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 263
Zhang, H., Qin, C., An, C., Zheng, X., Wen, S., Chen, W., Liu, X., Lv, Z., Yang, P., Xu, W., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01431-6 · Cited by 264
Target-Specific Precision of CRISPR-Mediated Genome Editing
Chakrabarti, A. M., Henser‐Brownhill, T., Monserrat, J., Poetsch, A. R., Luscombe, N. M., & Scaffidi, P. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.11.031 · Cited by 259
CRISPR–Cas9 genome editing in human cells occurs via the Fanconi anemia pathway
Richardson, C. D., Kazane, K. R., Feng, S. J., Zelin, E., Bray, N. L., Schäfer, A. J., Floor, S. N., & Corn, J. E. (2018) · Nature Genetics · doi:10.1038/s41588-018-0174-0 · Cited by 259
Potential pitfalls of CRISPR/Cas9‐mediated genome editing
Peng, R., Lin, G., & Li, J. (2016) · The FEBS Journal · doi:10.1111/febs.13586 · Cited by 213
Refining strategies to translate genome editing to the clinic
Cornu, T. I., Mussolino, C., & Cathomen, T. (2017) · Nature Medicine · doi:10.1038/nm.4313 · Cited by 252
Candida albicans Gene Deletion with a Transient CRISPR-Cas9 System
Min, K., Ichikawa, Y., Woolford, C. A., & Mitchell, A. P. (2016) · mSphere · doi:10.1128/msphere.00130-16 · Cited by 246
The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells
Lee, C. M., Cradick, T. J., & Bao, G. (2016) · Molecular Therapy · doi:10.1038/mt.2016.8 · Cited by 250
Review of CRISPR/Cas9 sgRNA Design Tools
Cui, Y., Xu, J., Cheng, M., Liao, X., & Peng, S. (2018) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-018-0298-z · Cited by 253
GuideScan software for improved single and paired CRISPR guide RNA design
Perez, A. R., Pritykin, Y., Vidigal, J. A., Chhangawala, S., Zamparo, L., Leslie, C. S., & Ventura, A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3804 · Cited by 245
A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing
Grünewald, J., Zhou, R., Lareau, C. A., Garcia, S. P., Iyer, S., Miller, B. R., Langner, L. M., Hsu, J. Y., Aryee, M. J., & Joung, J. K. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0535-y · Cited by 242
Self-citationPartial DNA-guided Cas9 enables genome editing with reduced off-target activity
Yin, H., Song, C.-Q., Suresh, S., Kwan, S.-Y., Wu, Q., Walsh, S., Ding, J., Bogorad, R. L., Zhu, L. J., Wolfe, S. A., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2559 · Cited by 240
High-throughput mapping of regulatory DNA
Rajagopal, N., Srinivasan, S., Kooshesh, K., Guo, Y., Edwards, M. D., Banerjee, B., Syed, T., Emons, B. J. M., Gifford, D. K., & Sherwood, R. I. (2016) · Nature Biotechnology · doi:10.1038/nbt.3468 · Cited by 238
Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes
Hess, G. T., Tycko, J., Yao, D., & Bassik, M. C. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.029 · Cited by 234
Webber, B. R., Lonetree, C.-L., Kluesner, M. G., Johnson, M. J., Pomeroy, E. J., Diers, M. D., Lahr, W. S., Draper, G. M., Slipek, N. J., Smeester, B. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13007-6 · Cited by 232
Walton, J. B., Blagih, J., Ennis, D. P., Leung, E. Y. L., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1272 · Cited by 236
Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq
Turchiano, G., Andrieux, G., Klermund, J., Blattner, G., Pennucci, V., el Gaz, M., Monaco, G., Poddar, S., Mussolino, C., Cornu, T. I., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.02.002 · Cited by 240
Selection of highly efficient sgRNAs for CRISPR/Cas9-based plant genome editing
Liang, G., Zhang, H., Lou, D., & Yu, D. (2016) · Scientific Reports · doi:10.1038/srep21451 · Cited by 240
In vivo base editing of post-mitotic sensory cells
Yeh, W.-H., Chiang, H., Rees, H. A., Edge, A. S. B., & Liu, D. R. (2018) · Nature Communications · doi:10.1038/s41467-018-04580-3 · Cited by 225
Targeted, efficient sequence insertion and replacement in rice
Lu, Y., Tian, Y., Shen, R., Yao, Q., Wang, M., Chen, M., Dong, J., Zhang, T., Li, F., Lei, M., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0581-5 · Cited by 225
Minimal PAM specificity of a highly similar SpCas9 ortholog
Chatterjee, P., Jakimo, N., & Jacobson, J. M. (2018) · Science Advances · doi:10.1126/sciadv.aau0766 · Cited by 229
CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells
Hoban, M. D., Lumaquin, D., Kuo, C. Y., Romero, Z., Long, J., Ho, M., Young, C. S., Mojadidi, M., Fitz-Gibbon, S., Cooper, A. R., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.148 · Cited by 220
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Biological plasticity rescues target activity in CRISPR knock outs
Smits, A. H., Ziebell, F., Joberty, G., Zinn, N., Mueller, W. F., Clauder-Münster, S., Eberhard, D., Fälth Savitski, M., Grandi, P., Jakob, P., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0614-5 · Cited by 219
A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture
O'Geen, H., Henry, I. M., Bhakta, M. S., Meckler, J. F., & Segal, D. J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv137 · Cited by 219
CRISPR/Cas9 advances engineering of microbial cell factories
Jakočiūnas, T., Jensen, M. K., & Keasling, J. D. (2015) · Metabolic Engineering · doi:10.1016/j.ymben.2015.12.003 · Cited by 225
Cas9-chromatin binding information enables more accurate CRISPR off-target prediction
Singh, R., Kuscu, C., Quinlan, A., Qi, Y., & Adli, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv575 · Cited by 217
The Functions and Unique Features of LncRNAs in Cancer Development and Tumorigenesis
Taniue, K., & Akimitsu, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020632 · Cited by 221
Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
Tao, J., Bauer, D. E., & Chiarle, R. (2023) · Nature Communications · doi:10.1038/s41467-023-35886-6 · Cited by 232
Schiroli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., Plati, T., Castiello, M. C., Sanvito, F., Gennery, A. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0820 · Cited by 214
CRISPR-Cas9 nuclear dynamics and target recognition in living cells
Ma, H., Tu, L., Naseri, A., Huisman, M., Zhang, S., Grünwald, D., & Pederson, T. (2016) · The Journal of Cell Biology · doi:10.1083/jcb.201604115 · Cited by 224
Garenne, D., Haines, M., Romantseva, E. F., Freemont, P. S., Strychalski, E. A., & Noireaux, V. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00046-x · Cited by 215
Design of highly functional genome editors by modelling CRISPR–Cas sequences
Ruffolo, J. A., Nayfach, S., Gallagher, J. P., Bhatnagar, A., Beazer, J., Hussain, R., Russ, J., Yip, J., Hill, E., Pačesa, M., et al. (2025) · Nature · doi:10.1038/s41586-025-09298-z · Cited by 233
Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq
Kim, D., Kim, S., Kim, S., Park, J., & Kim, J.-S. (2016) · Genome Research · doi:10.1101/gr.199588.115 · Cited by 208
Epigenome Editing: State of the Art, Concepts, and Perspectives
Kungulovski, G., & Jeltsch, A. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.12.001 · Cited by 212
Design and analysis of CRISPR–Cas experiments
Hanna, R. E., & Doench, J. G. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0490-7 · Cited by 216
CRISPR off-target analysis in genetically engineered rats and mice
Anderson, K. R., Haeussler, M., Watanabe, C. K., Janakiraman, V., Lund, J. M., Modrusan, Z. D., Stinson, J., Bei, Q., Buechler, A., Yu, C., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0011-5 · Cited by 210
Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9
Koo, T., Lee, J., & Kim, J. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0103 · Cited by 213
Li, J., Manghwar, H., Sun, L., Wang, P., Wang, G., Sheng, H., Zhang, J., Liu, H., Qin, L., Rui, H., et al. (2018) · Plant Biotechnology Journal · doi:10.1111/pbi.13020 · Cited by 211
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
Osborn, M. J., Webber, B. R., Knipping, F., Lonetree, C.-L., Tennis, N., DeFeo, A. P., McElroy, A. N., Starker, C. G., Lee, C., Merkel, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.197 · Cited by 201
The sound of silence: Transgene silencing in mammalian cell engineering
Cabrera, A., Edelstein, H. I., Glykofrydis, F., Love, K. S., Palacios, S., Tycko, J., Zhang, M., Lensch, S., Shields, C. E., Livingston, M., et al. (2022) · Cell Systems · doi:10.1016/j.cels.2022.11.005 · Cited by 217
Adenine base editing in an adult mouse model of tyrosinaemia
Song, C.-Q., Jiang, T., Richter, M., Rhym, L. H., Koblan, L. W., Zafra, M. P., Schatoff, E. M., Doman, J. L., Cao, Y., Dow, L. E., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0357-8 · Cited by 200
CRISPR-Cas9: a new and promising player in gene therapy
Xiao-Jie, L., Hui-Ying, X., Zun-Ping, K., Jin-Lian, C., & Li-Juan, J. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102968 · Cited by 200
Abadi, S., Yan, W. X., Amar, D., & Mayrose, I. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005807 · Cited by 208
Structural basis for Cas9 off-target activity
Pacesa, M., Lin, C.-H., Cléry, A., Saha, A., Arantes, P. R., Bargsten, K., Irby, M. J., Allain, F. H.-T., Palermo, G., Cameron, P., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.026 · Cited by 198
Prediction of the sequence-specific cleavage activity of Cas9 variants
Kim, N., Kim, H. K., Lee, S., Seo, J. H., Choi, J. W., Park, J., Min, S., Yoon, S., Cho, S.-R., & Kim, H. H. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0537-9 · Cited by 198
Highly Parallel Profiling of Cas9 Variant Specificity
Schmid-Burgk, J. L., Gao, L., Li, D., Gardner, Z., Strecker, J., Lash, B., & Zhang, F. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.02.023 · Cited by 197
Liu, Y., Zou, R. S., He, S., Nihongaki, Y., Li, X., Razavi, S., Wu, B., & Ha, T. (2020) · Science · doi:10.1126/science.aay8204 · Cited by 203
Boyle, E. A., Andreasson, J. O. L., Chircus, L. M., Sternberg, S. H., Wu, M. J., Guegler, C. K., Doudna, J. A., & Greenleaf, W. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700557114 · Cited by 205
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2015-09-618587 · Cited by 194
Metadata
- Authors
- Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., Aryee, M. J., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Tsai, Shengdar Q
- Joung, J Keith
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2014-12-16
- Volume
- 33
- Issue
- 2
- Pages
- 187-197
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4320685
- OpenAlex
- W2003797386
- Cited by
- 2,268
- References
- 39
- Citations by year
- 2026: 189 · 2025: 211 · 2024: 196 · 2023: 191 · 2022: 208 · 2021: 211 · 2020: 231 · 2019: 186 · 2018: 187 · 2017: 177 · 2016: 172 · 2015: 105 · 2014: 1
- FWCI
- 62.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM088040, F32GM105189)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR063070)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- GUIDE-seq, CRISPR-Cas nucleases, off-target cleavage, DNA double-strand breaks, genome-wide characterization, genome editing safety
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Cell Line, Humans, Oligodeoxyribonucleotides, Genome, Human, RNA Editing, DNA Breaks, Double-Stranded, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
